Learn More
Dyskinesia, a motor complication caused by prolonged administration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by activation of cAMP signaling and(More)
Background: DARPP-32 is implicated in L-DOPA-induced dyskinesia. Results: PKA-dependent phosphorylation of DARPP-32 in a distinct subset of striatal neurons is required for L-DOPA-induced activation(More)